PSC Multiplex Assays for Autism Gene Function Profiling
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current experimental models fail to capture the genetic heterogeneity and cell type-specific vulnerability of complex disorders like autism, making it difficult to understand how autism mutations affect brain development and clinical outcomes.
Innovation Solution
A pluripotent stem cell-based multiplex method involving multiple PSC lines with gene modifications is used to differentiate into disorder-related cell populations, allowing for the identification of genes associated with autism pathogenesis and the assessment of their functional impact on cellular phenotypes and signaling pathways, using techniques like CRISPR/Cas9 and ddPCR for gene frequency analysis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If individual mutations are studied in hPSCs, then gene function can be analyzed, but the laborious nature and line-to-line variability make the process inefficient
Solution Approach 1:
The patent merges multiple individual mutation analyses into a single multiplex assay by combining several PSC lines with different gene modifications into one culture. This allows simultaneous analysis of multiple genes and their phenotypic effects in a single experiment, dramatically improving productivity while maintaining measurement precision through standardized assay protocols.
Solution Approach 2:
The multiplex assay creates a universal platform that can analyze multiple genes, cell types, and phenotypic outcomes simultaneously. The same assay framework can be applied to different gene modifications and disorder models, making the system multi-functional and highly efficient for comprehensive genetic analysis.
2Adaptability or versatility
If multiple PSC lines with different gene modifications are analyzed together, then genetic heterogeneity can be captured, but line-to-line variability and cellular heterogeneity remain challenges
Solution Approach 1:
The patent applies local quality by analyzing specific phenotypic characteristics of interest (such as neuronal differentiation, synaptic function, or cellular morphology) within the context of multiple gene modifications. By focusing on specific local phenotypes rather than attempting to measure everything uniformly, the assay achieves reliable data while capturing genetic heterogeneity.
Solution Approach 2:
The multiplex assay incorporates feedback mechanisms through standardized readout protocols and statistical analysis that account for line-to-line variability. By establishing control conditions and using statistical methods to normalize data across different PSC lines, the system maintains reliability while preserving the ability to detect genetic heterogeneity effects.
3Loss of information
If comprehensive gene modification analysis is performed, then complete understanding of autism pathogenesis can be achieved, but the complexity and time required increase significantly
Solution Approach 1:
The patent merges multiple analysis steps into a single multiplex assay that simultaneously evaluates multiple genes, cell types, and phenotypic outcomes. This integrated approach provides comprehensive pathogenesis understanding without requiring separate experiments for each gene or phenotype, thereby reducing total analysis time while maintaining information completeness.
Solution Approach 2:
The assay design incorporates preliminary actions by pre-establishing control conditions, standardizing culture protocols, and preparing reference data before actual analysis. This allows rapid, comprehensive gene modification analysis to be performed efficiently without compromising the completeness of pathogenesis understanding.
Data Source
Figure 1A~1D
Figure 1E~1F
Figure 1G~1I
AI summary
The present disclosure relates to pluripotent stem cell (e.g., human PSC) based multiplex methods and compositions for identifying genes associated with the pathogenesis of a disorder (e.g., human disorder) and the responsiveness to certain treatments to such disorder. The present disclosure also provides genetic markers for identifying clinically relevant subpopulations of autism patients.